Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

Home
/
update
/
details

Hemogenyx Pharmaceuticals PLC: FLT3 Assay Prepared for Phase I Trials at MD Anderson

NextEdge Admin

10 Sep 2024

1 min 23 sec

Hemogenyx Pharmaceuticals,MD Anderson Cancer Center

Hemogenyx Pharmaceuticals plc , a clinical-stage biopharmaceutical company, has successfully developed a clinical-grade assay to measure FLT3 protein expression in acute myeloid leukemia (AML) cells. This assay is essential for accurately identifying and selecting patients for the upcoming Phase I clinical trials of the company’s HEMO-CAR-T product candidate. These trials are set to begin shortly at MD Anderson Cancer Center, a globally renowned cancer research and treatment facility, with plans to expand to the University of Pennsylvania Medical Center.

Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals, emphasized the significance of this achievement, stating that the FLT3 assay is a major milestone in advancing their HEMO-CAR-T product into clinical trials. By enabling precise patient selection, this assay brings the company closer to offering a potentially life-saving treatment for AML patients. The Phase I trials are expected to commence imminently.